Moderna

(NASDAQ: MRNA)
Health Care  |  Biotechnology
207.41 -11.44 -5.23%
Stock Price | June 14, 2021, 4 p.m.
0 Followers
Bid: 125.0
Ask: 212.04
Prev. Close: 218.85
52 Week Low: 54.21
52 Week High: 227.71
PE Ratio: 177.926829
Dividend Yield: %

Company Summary

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Read more Read less

Recently Viewed Tickers